Scarica l'app Stockscreener
10.90
5.71%
-0.66
Dopo l'orario di chiusura:
10.98
0.08
+0.73%
Precedente Chiudi:
$11.56
Aprire:
$11.61
Volume 24 ore:
2.83M
Relative Volume:
1.31
Capitalizzazione di mercato:
$1.33B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-5.396
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
-11.49%
1M Prestazione:
-32.55%
6M Prestazione:
-52.63%
1 anno Prestazione:
-76.61%
Intervallo 1D:
$10.83
$11.85
Intervallo di 1 settimana:
$10.83
$13.12
Portata 52W:
$10.80
$48.42
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
10.90 | 1.33B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
225.79 | 36.66B | 2.66B | 665.91M | 1.08B | 4.05 |
|
DOCS
Doximity Inc
|
72.37 | 13.58B | 516.85M | 174.11M | 217.38M | 0.87 |
|
SOLV
Solventum Corp
|
73.02 | 12.61B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
TEM
Tempus Ai Inc
|
68.09 | 10.72B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
108.60 | 9.41B | 1.15B | 96.70M | -161.99M | 1.09 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
Harvard, 10x Genomics Settle Patent Dispute With Vizgen - Harvard Crimson
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Alberta Investment Management Corp Makes New $3.21 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - Eastern Progress
Q1 EPS Estimates for 10x Genomics Lowered by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Shares Up 8.3%Still a Buy? - MarketBeat
Citigroup Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
10x Genomics (NASDAQ:TXG) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
10x Genomics' SWOT analysis: genomics firm faces NIH funding headwinds - Investing.com
10x Genomics (NASDAQ:TXG) Shares Gap Down on Disappointing Earnings - MarketBeat
Leerink Partners Downgrades 10x Genomics (NASDAQ:TXG) to Market Perform - MarketBeat
10x Genomics (NASDAQ:TXG) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Entropy Technologies LP Purchases 27,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Price Target Cut to $26.00 by Analysts at Morgan Stanley - MarketBeat
Leerink Partnrs Forecasts 10x Genomics Q1 Earnings - MarketBeat
Barclays Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
Canaccord Genuity Group Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
UBS Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $14.00 - MarketBeat
10x Genomics falls on quarterly EPS miss, 2025 revenue guidance concern - MSN
Morgan Stanley Trims Price Target on 10x Genomics to $26 From $28, Keeps Overweight Rating - Marketscreener.com
10x Genomics Inc Reports Q4 Revenue of $165M, Beating Estimates; EPS of -$0.40 Misses Expectations - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Has $82.05 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics Earnings Call: Innovations Amidst Revenue Challenges - TipRanks
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - Victoria Advocate
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties - Benzinga
10X Genomics stock plunges to 52-week low of $11.89 - MSN
10x Genomics, Inc. Provides Earnings Guidance for the Year 2025 -February 12, 2025 at 04:05 pm EST - Marketscreener.com
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN
UBS Adjusts Price Target on 10x Genomics to $14 From $20, Keeps Neutral Rating -February 13, 2025 at 10:09 am EST - Marketscreener.com
10x Genomics (NASDAQ:TXG) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat
10x Genomics Shares Tumble on Fear Over Cuts to NIH - Barron's
Leerink Partners Downgrades 10x Genomics to Market Perform From Outperform, Adjusts Price Target to $12 From $25 - Marketscreener.com
10x Genomics, Inc. SEC 10-K Report - TradingView
10x Genomics revenue increases 10% to USD 165M in Q4 2024 - Medical Buyer
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigat - GuruFocus.com
Barclays Cuts 10x Genomics (NASDAQ:TXG) Price Target to $18.00 - MarketBeat
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics: Q4 Earnings Snapshot - CT Insider
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025 - BioSpace
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings - Yahoo Finance
Earnings call transcript: 10X Genomics Q4 2024 misses EPS forecast, stock dips - Investing.com
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics: Q4 Earnings Snapshot -February 12, 2025 at 04:54 pm EST - Marketscreener.com
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Earnings Flash (TXG) 10x Genomics Reports Q4 Revenue $165M, vs. FactSet Est of $159.8M - Marketscreener.com
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10 X Genomics Inc Azioni (TXG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Nov 22 '24 |
Sale |
13.69 |
6,693 |
91,612 |
872,574 |
| Hindson Benjamin J. | See Remarks |
Nov 22 '24 |
Sale |
13.69 |
5,807 |
79,485 |
339,897 |
9.30%
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):